Curis to Present at Jefferies Virtual Healthcare Conference

On May 25, 2021 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 3:00 p.m. ET (Press release, Curis, MAY 25, 2021, View Source [SID1234580538]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company’s website at www.curis.com. A replay of the webcast will be available on the Curis website for approximately 90 days following the event.

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

On May 25, 2021 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team are scheduled to participate in the following virtual investor conferences in June (Press release, CRISPR Therapeutics, MAY 25, 2021, View Source [SID1234580537]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference
Date: Tuesday, June 1, 2021
Time: 1:00 p.m. ET

William Blair 41st Annual Growth Stock Conference
Date: Thursday, June 3, 2021
Time: 12:20 p.m. ET

Goldman Sachs 42nd Annual Global Healthcare Conference
Date: Tuesday, June 8, 2021
Time: 3:00 p.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of the webcasts will be archived on the Company’s website for 14 days following each presentation.

Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

On May 25, 2021 Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, reported that it will present at the Jefferies Virtual Healthcare Conference (Press release, Corvus Pharmaceuticals, MAY 25, 2021, View Source [SID1234580536]). The presentation will be on Thursday, June 3, 2021 from 4:00-4:25 pm ET .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.

New research demonstrates the value of patient-specific cancer models in studies of metastasis and drug resistance.

On May 25, 2021 At the annual meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) (AACR 2021: April 10 – 15 th and May 17-21 st) scientists from Cellaria Inc. (Wakefield, MA, USA), a scientific innovator with breakthrough tools for cancer research, reported that it will present new work demonstrating the value of patient-specific cancer models in studies of metastasis, and the associated development of drug resistance (Press release, Cellaria, MAY 25, 2021, View Source [SID1234580535]). Cellaria offers models that accurately represent a diverse range of disease types, progression grades and genetic profiles. These enable researchers to study disease pathways and develop patient-specific therapies more effectively. The new research demonstrates the utility of patient-specific ovarian, breast and pancreatic cancer models in studies of the tumor microenvironment and the metastatic niche, illustrating their potential to improve the likelihood of success in clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cellaria’s poster is entitled ‘Modeling the metastatic niche interactions between patient tumor and mesenchymal cells to identify drivers of chemotherapy drug resistance’. The process of metastasis involves cancer cells moving to and thriving in a foreign microenvironment. The Metastatic niche facilitates this process by performing functions such as anchorage, proliferation, and expansion. In this process, mesenchymal stem cells (MSC) sourced from adipose tissue were co-cultured in three-dimensional tumor spheroids to simulate the microenvironment of the metastatic niche. The resulting models were then tested with a broad range chemotherapeutic agent. The impact of different MSC seeding ratios on the resulting response curve was investigated.

The results show that chemotherapeutic response is dependent on MSC seeding ratio, but that even at low levels MSCs have an impact on the drug response of metastatic tumor spheroids. These effects are observed across the patient profile spectrum, with each cancer type. Though there is detectable variation, the strength of the effect is not homogeneous. Disease type, MSC ratio, and drug utilized all influence the observed results. A key conclusion from the work is that the models provide a reproducible, easily scaled tool for assessing the efficacy of chemotherapeutic drugs with respect to metastatic tumors, thereby supporting the development of more effective, precisely targeted therapies.

The Bristol Myers Squibb Foundation Announces First Global Cancer Disparities Grants in Brazil

On May 25, 2021 The Bristol Myers Squibb Foundation reported that it has launched a new initiative in Brazil, awarding four grants aimed at improving the delivery of high-quality care for lung cancer and skin cancer to medically underserved and rural communities (Press release, Bristol-Myers Squibb, MAY 25, 2021, View Source;First-Global-Cancer-Disparities-Grants-in-Brazil/default.aspx [SID1234580534]). The organizations that have received grants are focused on community outreach and disease education, strengthening collaborations among primary care physicians and oncologists, and supporting efforts to promote early diagnosis and treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These four grants are part of the Bristol Myers Squibb Foundation’s Global Cancer Disparities Initiative, which supports grantees in Brazil, China, nine countries in Africa and the United States. The grantees in Brazil exemplify the Foundation’s strategy to identify organizations that are pioneering innovative health equity solutions and provide funding to enable them to develop, test, measure and demonstrate the effectiveness of programs to improve access to high-quality healthcare.

"Even before COVID-19, disparities in care for lung cancer and melanoma patients in Brazil have long been driven by barriers both inside and outside the clinic," said John Damonti, president of the Bristol Myers Squibb Foundation. "These grantee projects have the potential to strengthen health systems, community education and patient support services, and serve as examples for advancing equity in cancer care throughout Latin America, particularly in this difficult era of COVID-19."

Lung cancer is the leading cause of cancer death in Brazil, and skin cancers including melanoma occur at three to four times the rate of the global average. Moreover, the COVID-19 pandemic has severely disrupted patient education and support programs as well as medical services for patients, increasing the vulnerabilities of patients and those who are at risk of diagnosis.

In 2020, the Bristol Myers Squibb Foundation issued a special request for proposals for programs that would enable 1) people at high-risk for cancer to commence screening, detection, diagnosis, treatment and palliative care, and 2) current cancer patients to continue to receive clinical care and supportive services in the era of COVID19.

Organizations that were awarded grants are leading organizations with track records of successful program implementation and commitment to health equity. The organizations are:

Barretos Cancer Hospital. Barretos Cancer Hospital was created in 1967 to meet the needs of public cancer treatment outside the city of São Paulo and has several branches in Brazil. It was awarded two grants, each for a separate project. One project will improve skin cancer screening through teledermatology and improve the workflow and referral pathway to link patients to diagnostic and treatment services. The other project will establish lung cancer and melanoma mobile units to identify high-risk individuals and implement telehealth services at health units to provide access to diagnosis and treatment and to retain patients in care.

Instituto Oncoguia. With its Bristol Myers Squibb Foundation grant, Instituto Oncoguia, a leading non-governmental organization in fighting cancer in Brazil, will be able to employ patient navigators to provide personalized support to help patients receive diagnoses and begin treatment without unnecessary delays or loss to follow-up for patients with lung cancer.

Irmandade Santa Casa de Porto Alegre. The oldest hospital in Rio Grande do Sul, Irmandade Santa Casa de Porto will use the Bristol Myers Squibb Foundation grant to integrate specialized health care in oncology with primary health care through teleconsultation and patient navigation to promote early diagnosis of lung cancer and expedite access to providers at specialty cancer hospitals.